Emergent BioSolutions (NYSE:EBS) Upgraded at StockNews.com

StockNews.com upgraded shares of Emergent BioSolutions (NYSE:EBS) from a hold rating to a buy rating in a research note released on Tuesday morning.

Other research analysts have also issued research reports about the stock. Benchmark upped their price target on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Rodman & Renshaw reiterated a “buy” rating and set a $16.00 target price on shares of Emergent BioSolutions in a research note on Friday, September 13th.

Emergent BioSolutions Stock Performance

Shares of NYSE EBS opened at $7.72 on Tuesday. Emergent BioSolutions has a 12 month low of $1.42 and a 12 month high of $15.10. The stock has a 50 day moving average of $8.66 and a 200-day moving average of $7.97. The company has a current ratio of 2.88, a quick ratio of 1.47 and a debt-to-equity ratio of 1.30. The company has a market capitalization of $418.27 million, a P/E ratio of -1.88 and a beta of 1.57.

Institutional Trading of Emergent BioSolutions

A number of institutional investors have recently bought and sold shares of EBS. CWM LLC lifted its position in shares of Emergent BioSolutions by 32,706.7% during the 2nd quarter. CWM LLC now owns 4,921 shares of the biopharmaceutical company’s stock valued at $34,000 after acquiring an additional 4,906 shares during the period. Tidal Investments LLC acquired a new position in shares of Emergent BioSolutions in the 1st quarter valued at approximately $34,000. Meeder Asset Management Inc. bought a new stake in shares of Emergent BioSolutions during the 2nd quarter worth approximately $41,000. Mirae Asset Global Investments Co. Ltd. bought a new position in Emergent BioSolutions in the first quarter valued at approximately $57,000. Finally, Price T Rowe Associates Inc. MD increased its stake in Emergent BioSolutions by 22.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 23,943 shares of the biopharmaceutical company’s stock valued at $61,000 after acquiring an additional 4,409 shares during the last quarter. Institutional investors own 78.40% of the company’s stock.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.